Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 4/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | FDPS | P14324 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.38 |
| ▸ | CHRNG | P07510 | 1/20 | 0.38 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3691691 | 0.95 | FDPS (0.48) | ADORA2ACYP1A2TSHRFDPSLTA4H | |
| SCHEMBL8649807 | 0.94 | FDPS (0.47) | ADORA2ACYP1A2TSHRFDPSLTA4H | |
| SCHEMBL10163117 | 0.90 | FDPS (0.51) | ADORA2ACYP1A2TSHRFDPSLTA4H | |
| SCHEMBL31024294 | 0.90 | FDPS (0.51) | ADORA2ACYP1A2TSHRFDPSLTA4H | |
| SCHEMBL28418912 | 0.88 | FDPS (0.43) | ADORA2ACYP1A2TSHRFDPSLTA4H | |
| SCHEMBL5017550 | 0.85 | FDPS (0.50) | ADORA2ACYP1A2TSHRFDPSLTA4H | |
| SCHEMBL5017009 | 0.83 | FDPS (0.49) | ADORA2ACYP1A2TSHRFDPSLTA4H | |
| SCHEMBL5017010 | 0.83 | FDPS (0.49) | ADORA2ACYP1A2TSHRFDPSLTA4H | |
| SCHEMBL11249434 | 0.83 | FDPS (0.49) | ADORA2ACYP1A2TSHRFDPSLTA4H | |
| SCHEMBL7102528 | 0.83 | FDPS (0.49) | ADORA2ACYP1A2TSHRFDPSLTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108912055-B | Method for synthesizing antiviral drug cidofovir intermediate and bucyclovir intermediate | 河南师范大学 | 2020-06-30 | — | — | CN | claimed |
| CN-108912055-A | A method of synthesis antiviral agent cidofovir and Buciclovir | 河南师范大学 | 2018-11-30 | — | — | CN | claimed |
| CN-101258834-A | Method for breeding high content stevioside genetic material | UNIV GUILIN TECH GUT (CN) | 2008-09-10 | — | — | CN | claimed |
| CN-108912055-B | Method for synthesizing antiviral drug cidofovir intermediate and bucyclovir intermediate | 河南师范大学 | 2020-06-30 | — | — | CN | disclosed |
| CN-108912055-A | A method of synthesis antiviral agent cidofovir and Buciclovir | 河南师范大学 | 2018-11-30 | — | — | CN | disclosed |
| CN-104918939-B | Purine inhibitors of human phosphatidylinositol 3-kinase | 默沙东公司 | 2018-08-28 | — | — | CN | disclosed |
| CN-108342002-A | A kind of dynamic aggregation object and its application with hybrid cross-linked network | 翁秋梅 | 2018-07-31 | — | — | CN | disclosed |
| CN-108342037-A | A kind of energy-absorbing method based on hybrid cross-linked network dynamic polymer | 翁秋梅 | 2018-07-31 | — | — | CN | disclosed |
| US-9390864-B2 | Additives for dye-sensitized solar cells | MERCK PATENT GMBH (DE) | 2016-07-12 | — | — | US | disclosed |
| US-20150340165-A1 | ADDITIVES FOR DYE-SENSITIZED SOLAR CELLS | MERCK PATENT GMBH (DE) | 2015-11-26 | — | — | US | disclosed |
| US-9159499-B2 | Additives for dye-sensitized solar cells | MERCK PATENT GMBH (DE) | 2015-10-13 | — | — | US | disclosed |
| US-7589067-B2 | 6, 11-bridged tricyclic macrolides | ENANTA PHARMACEUTICALS, INC. (US) | 2009-09-15 | — | — | US | disclosed |
| CN-101258834-A | Method for breeding high content stevioside genetic material | UNIV GUILIN TECH GUT (CN) | 2008-09-10 | — | — | CN | disclosed |
| US-7407942-B2 | 3,6-bridged 9,12-oxolides | EMATA PHARMACEUTICALS, INC (US) | 2008-08-05 | — | — | US | disclosed |
| US-20080039406-A1 | 3,6-BRIDGED TYLOSIN DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20070244160-A1 | 6-11 Bicyclic Ketolide Derivatives | OR YAT SUN | 2007-10-18 | — | — | US | disclosed |
| US-20070232554-A1 | 3,6-Bridged 9,12-oxolides | ENATA PHARMACEUTICALS, INC. | 2007-10-04 | — | — | US | disclosed |
| US-20070082853-A1 | 6, 11-bridged tricyclic macrolides | ENANTA PHARMACEUTICAL, INC. | 2007-04-12 | — | — | US | disclosed |
| EP-1349857-A1 | PURINE DERIVATIVES AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RESEARCH LIMITED (GB) | 2003-10-08 | — | — | EP | disclosed |
| WO-2002055521-A1 | PURINE DERIVATIVES AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RESEARCH LIMITED (GB) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244160-A1 | 6-11 Bicyclic Ketolide Derivatives | AKR1C2, AKR1C3, AKR1C1 | ADORA2A 3413/4885CYP1A2 104/4885TSHR 4172/4885 |
| US-20070082853-A1 | 6, 11-bridged tricyclic macrolides | CYP2B6, CYP2D6, ABCB11 | ADORA2A 4014/4885CYP1A2 59/4885TSHR 3740/4885 |
| US-20080039406-A1 | 3,6-BRIDGED TYLOSIN DERIVATIVES | ABCB11, ABCB1, CYP2B6 | ADORA2A 4717/4885CYP1A2 164/4885TSHR 4052/4885 |
| US-20070232554-A1 | 3,6-Bridged 9,12-oxolides | CYP2C9, CYP2C19, CYP2D6 | ADORA2A 3840/4885CYP1A2 38/4885TSHR 4466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.